Trending Stock News

Bb Biotech Ag Has Cut Halozyme Therapeutics (HALO) Position; Vornado Realty Trust (VNO) Had 8 Bulls

Vornado Realty Trust (NYSE:VNO) Logo

Among 14 analysts covering Vornado Realty Trust (NYSE:VNO), 8 have Buy rating, 0 Sell and 6 Hold. Therefore 57% are positive. Vornado Realty Trust had 35 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Overweight” rating by Barclays Capital given on Tuesday, October 20. The stock has “Buy” rating by Sandler O’Neill on Friday, January 19. The stock of Vornado Realty Trust (NYSE:VNO) earned “Buy” rating by Evercore on Monday, May 16. The rating was downgraded by J.P. Morgan to “Hold” on Friday, December 15. Sandler O’Neill maintained Vornado Realty Trust (NYSE:VNO) rating on Wednesday, February 14. Sandler O’Neill has “Buy” rating and $75.0 target. The firm has “Equalweight” rating given on Tuesday, July 19 by Barclays Capital. The firm has “Equal-Weight” rating given on Tuesday, January 26 by Barclays Capital. The rating was upgraded by SunTrust to “Buy” on Monday, January 22. The stock of Vornado Realty Trust (NYSE:VNO) has “In-Line” rating given on Monday, December 4 by Evercore. Credit Suisse upgraded it to “Outperform” rating and $108 target in Tuesday, April 12 report. See Vornado Realty Trust (NYSE:VNO) latest ratings:

08/04/2018 Broker: BMO Capital Markets Rating: Buy New Target: $85.0000 Maintain
26/03/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $83 New Target: $78 Maintain
16/03/2018 Broker: BMO Capital Markets Rating: Outperform New Target: $85 Initiates Coverage On
15/03/2018 Broker: Sandler O’Neill Rating: Buy New Target: $76.0 Maintain
06/03/2018 Broker: SunTrust Rating: Buy New Target: $78.0 Maintain
14/02/2018 Broker: Sandler O’Neill Rating: Buy New Target: $75.0 Maintain
13/02/2018 Broker: Stifel Nicolaus Rating: Hold New Target: $66.0 Maintain
22/01/2018 Broker: SunTrust Rating: Buy Upgrade
19/01/2018 Broker: Sandler O’Neill Rating: Buy New Target: $85.0 Maintain
15/12/2017 Broker: J.P. Morgan Rating: Hold New Target: $92.0 Downgrade

Bb Biotech Ag decreased Halozyme Therapeutics Inc. (HALO) stake by 1.23% reported in 2017Q4 SEC filing. Bb Biotech Ag sold 105,914 shares as Halozyme Therapeutics Inc. (HALO)’s stock declined 6.13%. The Bb Biotech Ag holds 8.52M shares with $172.62 million value, down from 8.63 million last quarter. Halozyme Therapeutics Inc. now has $2.70 billion valuation. The stock decreased 1.57% or $0.3 during the last trading session, reaching $18.86. About 816,952 shares traded. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has risen 32.10% since April 22, 2017 and is uptrending. It has outperformed by 20.55% the S&P500.

Vornado Realty Trust is a publicly owned real estate investment trust. The company has market cap of $13.27 billion. The firm invests in the real estate markets of the United States. It has a 77.15 P/E ratio. It makes investments in commercial real estate properties to create its portfolio.

Investors sentiment decreased to 0.99 in Q4 2017. Its down 0.06, from 1.05 in 2017Q3. It worsened, as 34 investors sold Vornado Realty Trust shares while 135 reduced holdings. 49 funds opened positions while 118 raised stakes. 153.63 million shares or 4.19% less from 160.36 million shares in 2017Q3 were reported. 1832 Asset Mngmt Lp owns 83,000 shares. Zurcher Kantonalbank (Zurich Cantonalbank) holds 67,957 shares. Caisse De Depot Et Placement Du Quebec holds 200,848 shares. Gulf National Bank & Trust (Uk) reported 0.05% of its portfolio in Vornado Realty Trust (NYSE:VNO). Glg Ltd Liability Corp accumulated 7,735 shares. Meiji Yasuda Asset Mngmt accumulated 6,579 shares. Ls Invest Advsrs Ltd Liability Com reported 0.03% stake. Beck Mack And Oliver Ltd holds 0.01% or 5,504 shares in its portfolio. Commonwealth Of Pennsylvania School Empls Retrmt reported 14,270 shares. Cbre Clarion Secs Lc has 2.94% invested in Vornado Realty Trust (NYSE:VNO) for 3.28 million shares. Advantus Capital Mgmt owns 29,007 shares for 0.06% of their portfolio. Franklin invested 0.15% in Vornado Realty Trust (NYSE:VNO). Gateway Investment Advisers Ltd Liability holds 0.01% or 9,958 shares. North Star Inv holds 0% of its portfolio in Vornado Realty Trust (NYSE:VNO) for 43 shares. Dynamic Cap has invested 0.13% in Vornado Realty Trust (NYSE:VNO).

The stock decreased 1.18% or $0.78 during the last trading session, reaching $65.42. About 990,696 shares traded. Vornado Realty Trust (NYSE:VNO) has declined 18.58% since April 22, 2017 and is downtrending. It has underperformed by 30.13% the S&P500.

Among 10 analysts covering Halozyme Therapeutics (NASDAQ:HALO), 6 have Buy rating, 0 Sell and 4 Hold. Therefore 60% are positive. Halozyme Therapeutics had 24 analyst reports since August 11, 2015 according to SRatingsIntel. The stock has “Neutral” rating by Citigroup on Friday, January 6. The firm has “Overweight” rating by Barclays Capital given on Tuesday, September 22. The firm has “Buy” rating by Canaccord Genuity given on Wednesday, July 26. The firm earned “Overweight” rating on Wednesday, February 21 by JP Morgan. The firm has “Overweight” rating by Piper Jaffray given on Friday, September 16. The stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) earned “Buy” rating by Deutsche Bank on Wednesday, January 24. The company was initiated on Wednesday, November 18 by Citigroup. The rating was maintained by Canaccord Genuity on Wednesday, November 8 with “Buy”. JMP Securities maintained the stock with “Market Outperform” rating in Tuesday, August 11 report. The stock has “Buy” rating by Deutsche Bank on Friday, September 15.

Analysts await Halozyme Therapeutics, Inc. (NASDAQ:HALO) to report earnings on May, 10 after the close. They expect $-0.21 earnings per share, up 19.23% or $0.05 from last year’s $-0.26 per share. After $0.85 actual earnings per share reported by Halozyme Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -124.71% negative EPS growth.

Investors sentiment increased to 1.66 in 2017 Q4. Its up 0.40, from 1.26 in 2017Q3. It improved, as 13 investors sold HALO shares while 45 reduced holdings. 39 funds opened positions while 57 raised stakes. 118.31 million shares or 0.18% less from 118.53 million shares in 2017Q3 were reported. Creative Planning, Kansas-based fund reported 87,682 shares. Millennium Management Ltd Limited Liability Company invested in 1.48 million shares. 17,347 were reported by Aperio Ltd Co. Snyder Mgmt LP holds 2.39% or 2.37M shares. State Of Wisconsin Invest Board invested in 0.01% or 117,900 shares. Savings Bank Of Ny Mellon Corporation holds 0.01% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 1.86 million shares. Proshare Advsr Lc stated it has 94,410 shares or 0.01% of all its holdings. Bessemer Group Incorporated reported 0% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Timpani Mngmt Lc stated it has 155,066 shares. Prelude Cap Ltd Llc stated it has 0% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Pnc Fin Gru owns 39,694 shares for 0% of their portfolio. Washington-based Parametric Associates Ltd Llc has invested 0% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). The Illinois-based Chicago Equity Prtnrs has invested 0.14% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Blackrock invested in 0.01% or 12.09M shares. Moreover, Prudential Financial has 0.03% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO).

Vornado Realty Trust (NYSE:VNO) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *